8.155

3.96% -0.335

Ocular Therapeutix Inc (OCUL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt OCUL? Forum Prognose

Schlusskurs vom Vortag:

$8.49

Offen:

$8.51

24-Stunden-Volumen:

1.78M

Relative Volume:

0.30

Marktkapitalisierung:

$1.77B

Einnahmen:

$51.95M

Nettoeinkommen (Verlust:

$-265.94M

KGV:

-5.6695

EPS:

-1.4384

Netto-Cashflow:

$-216.89M

1W Leistung:

+10.19%

1M Leistung:

-20.60%

6M Leistung:

-25.67%

1J Leistung:

+28.31%

1-Tages-Spanne:

$8.115

$8.54

1-Wochen-Bereich:

$7.53

$8.75

52-Wochen-Spanne:

$5.80

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Firmenname

Ocular Therapeutix Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

781-357-4000

Adresse

15 CROSBY DRIVE, BEDFORD, MA

Mitarbeiter

325

Twitter

@OCUTX

Nächster Verdiensttermin

2025-03-03

Neueste SEC-Einreichungen

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OCUL Ocular Therapeutix Inc	8.15	1.85B	51.95M	-265.94M	-216.89M	-1.4384
VRTX Vertex Pharmaceuticals Inc	433.59	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.90	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.75	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.75	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	164.04	35.01B	606.42M	-1.28B	-997.58M	-6.403

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-15	Eingeleitet	Chardan Capital Markets	Buy
2025-04-08	Eingeleitet	William Blair	Outperform
2025-03-18	Eingeleitet	RBC Capital Mkts	Outperform
2025-03-11	Eingeleitet	Needham	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-06-20	Hochstufung	TD Cowen	Hold → Buy
2024-05-31	Fortgesetzt	Piper Sandler	Overweight
2024-02-09	Eingeleitet	BofA Securities	Buy
2023-04-21	Eingeleitet	Robert W. Baird	Outperform
2022-08-10	Fortgesetzt	Berenberg	Buy
2021-08-10	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-17	Eingeleitet	Berenberg	Buy
2020-11-13	Bestätigt	Raymond James	Strong Buy
2020-08-10	Bestätigt	H.C. Wainwright	Buy
2020-03-03	Hochstufung	Raymond James	Outperform → Strong Buy
2019-05-21	Herabstufung	Cowen	Outperform → Market Perform
2019-05-21	Bestätigt	H.C. Wainwright	Buy
2019-05-21	Herabstufung	Raymond James	Strong Buy → Outperform
2018-12-03	Bestätigt	Cantor Fitzgerald	Overweight
2018-11-15	Eingeleitet	Raymond James	Strong Buy
2018-09-07	Eingeleitet	Piper Jaffray	Overweight
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-26	Eingeleitet	H.C. Wainwright	Buy
2017-07-12	Bestätigt	Cantor Fitzgerald	Overweight
2017-06-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Eingeleitet	Cantor Fitzgerald	Overweight
2016-11-15	Bestätigt	RBC Capital Mkts	Outperform
2016-08-11	Eingeleitet	JMP Securities	Mkt Outperform
2016-02-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten

Apr 05, 2026

HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN

Apr 02, 2026

OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill

Apr 02, 2026

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm

Apr 02, 2026

Apr 01, 2026

Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Apr 01, 2026

OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai

Apr 01, 2026

Ocular lines up April talks on wet AMD trial data and retinal disease - Stock Titan

Apr 01, 2026

Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey

Apr 01, 2026

Mar 31, 2026

Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo

Mar 31, 2026

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - MarketBeat

Mar 31, 2026

Mar 30, 2026

OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com

Mar 30, 2026

Mar 29, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat

Mar 29, 2026

Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat

Mar 29, 2026

Mar 28, 2026

Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm

Mar 28, 2026

Mar 27, 2026

What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance

Mar 27, 2026

Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan

Mar 27, 2026

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com

Mar 27, 2026

H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK

Mar 27, 2026

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo

Mar 27, 2026

Mar 26, 2026